Swept‑source OCT detects nonexudative MNV

Modern Retina reported on May 23 that swept-source optical coherence tomography angiography, or SS-OCTA, can identify treatment-naive nonexudative macular neovascularization in eyes with dry age-related macular degeneration. The report, reviewed by Philip J. Rosenfeld, MD, PhD, described these lesions as an increasingly recognized stage of AMD that may be missed on routine structural imaging alone. (modernretina.com) Rosenfeld said the lesions are asymptomatic, but their detection matters because they appear to precede exudative disease in at least some patients. PubMed lists a 2021 Investigative Ophthalmology & Visual Science study on the “swept-source OCT angiographic characteristics” of treatment-naive nonexudative macular neovascularization before exudation. (pubmed.ncbi.nlm.nih.gov) That study set out to describe how these lesions look on SS-OCTA in AMD eyes before fluid or hemorrhage develops — the practical moment when clinicians are trying to decide whether a patient is still “dry.” ### What exactly is being detected before the eye becomes “wet”? Nonexudative macular neovascularization refers to new abnormal vessels in the macula without the leakage that defines exudative, or wet, AMD. A PubMed-indexed study and a later review in Ophthalmology Retina describe these lesions as treatment-naive vascular growth in the outer retina or sub-retinal pigment epithelial space without signs of exudation. (modernretina.com) Rosenfeld told Modern Retina that the lesions are important precisely because patients may have no symptoms when they are present. That means the issue is not symptom recognition but imaging recognition during follow-up visits for dry AMD. (pubmed.ncbi.nlm.nih.gov) ### Why does swept-source OCTA matter more than a standard scan here? SS-OCTA adds angiographic information to OCT imaging, allowing clinicians to visualize blood flow within neovascular complexes rather than only the structural aftermath of leakage. Modern Retina said that capability allows treatment-naive nonexudative MNV to be detected accurately in dry AMD eyes. (pubmed.ncbi.nlm.nih.gov) Modern Retina also reported separately that SS-OCTA has become a major tool for imaging the choriocapillaris in AMD. That broader use matters because the same platform is being positioned not just as a research device, but as part of how retina specialists characterize disease biology earlier in the course of AMD. (modernretina.com) ### How common are these lesions in practice? JAMA Ophthalmology published a prospective cohort study online on April 9, 2026, examining fellow-eye nonexudative MNV in AMD patients with unilateral new exudative disease. The study found that 1 in 5 fellow eyes had a double-layer sign on OCT, and said accurate prevalence estimates of nonexudative MNV are needed for clinical trial planning. (modernretina.com) An earlier natural-history study in Ophthalmology reported on the prevalence, incidence and course of subclinical neovascularization detected with swept-source OCTA in nonexudative AMD. Later reviews have focused on exudative conversion rates, reflecting the central clinical question after detection: not whether the lesion exists, but how likely it is to progress. (modernretina.com) ### Does finding nonexudative MNV change treatment right away? Modern Retina framed the immediate value as earlier monitoring and treatment planning rather than automatic treatment at detection. The report said identifying treatment-naive nonexudative MNV may help clinic workflow by flagging dry AMD patients who need closer surveillance for conversion. (jamanetwork.com) Nature’s Eye and Scientific Reports literature has focused on the short-term natural history and two-year exudation risk of nonexudative MNV detected with swept-source OCTA. Those studies do not by themselves establish a universal treatment trigger, but they do support closer follow-up once a lesion is found. (sciencedirect.com) ### Where does this leave retina clinics now? May 23 is the latest publication date for the Modern Retina explainer, but the evidence base it cites is older and includes 2021 imaging-characterization work and newer 2026 prevalence data. For retina specialists, the next practical step is not a new drug decision in the article itself; it is whether SS-OCTA is incorporated into dry AMD surveillance for patients in whom subclinical neovascularization would alter follow-up intensity or treatment planning. (modernretina.com) (nature.com)